Medicinal Chemistry and all of Oncology’s integrated chemical core technologies are set up to provide the synthetic chemistry output and medicinal chemistry competence for effectively advancing the drug ...
On Friday April 20th, at 1.30 PM, Dr. Marina Mapelli from the Institute of European Institute of Oncology in Milano, Italy will present an Oncology Seminar entitled "Inscuteable and NuMa bind competitively ...
On Friday April 13th, at 1.30 PM, Dr. Francesco Bertoni from the Institute of Oncology Research in Bellinzona, Switzerland, will present an Oncology Seminar entitled "Array-CGH provides insights into the ...
On Friday March 23, at 2.30 PM, Dr. Paul Diehl from the Cellecta, in Mountain View(CA), will present an Oncology Seminar entitled “RNAi Genetic Screening for Drug Target Discovery”. Cellecta is a small ...
On Friday March 9th, at 1.30 PM, Prof. Riccardo Bellazzi from the University of Pavia and Biomedical Informatics Laboratory, IRCCS Fondazione S. Maugeri, Pavia will present an Oncology Seminar entitled ...
6. Licensing e Collaborazioni
(Oncology (it))
NMS Oncology is strategically committed to partnerships to promote discovery and development of innovative cancer treatments. Thus, we are open to establish R&D collaborative undertakings by applying ...
7. Milciclib
(Pipeline (it))
... PHA-848125 administered with prolonged schedules of administration (American Society of Clinical Oncology Annual Meeting2010,46th:June 7(Abs 3065)) Phase I study of the oral CDK-TRKA inhibitor PHA-848125 ...
On Friday January 20th, at 1.30 PM, Dr. Andrea Necchi from the Department of Medicine, Medical Oncology 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori in Milan will present an Oncology Seminar ...
9. Core services
(M.I.O. (it))
... to EVMPD via EV-Web Acknowledgment Management Clinical Data Management Data Management Plan Case Report Form, Design and Development (extensive library of Oncology specific modules available) ...
10. Partnerships
(M.I.O. (it))
Partnership with Lombardy Oncology Network (Rete Oncologica Lombarda) and Lombardy Hematology Network (Rete Ematologica Lombarda). Partnership with renowned European and US development sites: ...
11. Expertise
(M.I.O. (it))
... experience in oncology clinical development from cytotoxics to hormonals and targeted therapies: INDICATIONS Acute Leukemia Chronic Leukemia Multiple Myeloma Myelodisplastic Syndromes ...
Milano International Oncology operates as your partner in the clinical development and life-cycle management of compounds from first-time-in-man up to phase IV. MIO offers a full range of clinical developments ...
13. Capabilities
(Oncology (it))
Our expanding discovery and development capabilities array includes classical and innovative approaches to drug discovery, fully integrated within the Oncology division.  ...
14. Purinome Platform
(Technology Platforms (it))
The generation of novel chemotypes in support of our oncology research projects expanded in recent years from a canonical design of kinase targeted compound libraries to a broader interpretation of purinome ...
15. Kinase Platform
(Technology Platforms (it))
Our Oncology unit has developed a methodological platform to discover small molecule kinase inhibitors, which we refer to as the ‘Kinase Platform’. A panel of over 90 cloned and expressed kinases is ...
16. Danusertib
(Pipeline (it))
...  Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors, Journal of Clinical Oncology 2009,27:30(5094-5101) A ...
17. Nemorubicin
(Pipeline (it))
... Oncology Annual Meeting 2009,May 31(Abs 4593) Sun Y,Yang J, Luo P, et al. Efficacy of Nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary ...
18. Pubblicazioni
(Science Corner (it))
... R, Carpinelli P, Laffranchi B, de Jonge M. Journal Clinical Oncology (2009) 27(30), 5094-5101 Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships ...
19. Seminari di Oncologia
(Science Corner (it))
... for asymmetric cell divisions Marina Mapelli European Institute of Oncology, Milano April 13, 2012 (1:30 PM) ArrayCGH provides insights into the pathogenesis of diffuse large B-cell lymphomas Francesco ...
20. Eventi e Congressi
(Science Corner (it))
... personalized cancer medicine Paris, FR Web link Oral presentation A successful interaction between Academia, Pharma (Nerviano Medical Sciences) and Oncology network ofLombardy A. Isacchi, A. Galvani ...
21. About NMS Oncology
(Oncology (it))
We fight cancer Our mission is to identify innovative agents for clinical development in areas of unmet medical needs in Oncology. From the “Discovery” phase onwards to clinical phase II, our aim is ...
Nerviano – 15 March, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Nerviano – 18 January, 2011 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
Before the Italian Ambassador to Washington, Giulio Terzi di Sant'Agata, the current Chairman of Nerviano Medical Sciences, Alberto Sciumè, and John DeYoung, Vice President Oncology Business Development ...
Nerviano Italy, 8 October 2009 - Nerviano Medical Sciences today announced a publication in the peer-reviewed scientific journal, Journal of Clinical Oncology (*), of the first clinical trial performed ...
... the clinical experimentation of our Cdc7 inhibitor - explains Dr. Francesco Colotta, NMS Oncology VP - first of all represents an acknowledgment of the quality and innovation of Italian research in the ...
Nerviano, 21 October, 2008 - Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies ...
... in these days at the American Society of Clinical Oncology (ASCO) Conference, being held in Chicago from 30th May to 3rd June. For these three new compounds the scientists' attention will be called ...
... at Nerviano Medical Sciences Srl. (NMS), one of the leading oncology R&D companies in Europe. The article focuses on a new anti-cancer molecule that inhibits Cdc7, a target protein implicated in ...
... (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced an agreement with Genentech, ...
... facility in Italy and one of the largest oncology-focused, integrated discovery and development organizations in Europe. It was incorporated in May 2004 following a spin-off from Pfizer.Today NMS is a ...
... a privately held oncology company, in a stock for stock merger valued at $20 million. SMi stockholders could also receive a maximum of $15 million in additional consideration, payable in either cash or ...
... stage development of active compounds against new oncology targets provided by Bristol-Myers Squibb. Terms of the multi-year risk sharing collaboration include the potential for up to $150 million in clinical ...